Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

Delayed Diagnosis and Diagnostic Imprinting in Pediatric CNS Tumors:…

Ibrahim Qaddoumi

cfDNA for Liquid Biopsy for Patients With Glioblastoma

Penn Medicine's 11th Neuro-Oncology Brain Tumor Symposium 2024

S. Bagley

2024 Neuro-Oncology Update: Brain Tumors

Scripps Health

T. McGranahan

Year in Review 2024 - Top Clinical Trials in Neuro-Oncology

Oncology 2024 Year in Review

S. Bagley

Overview of CNS Cancers

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

V. Venur

Overview and Updates in Brain Tumors

Henry Friedman

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

Best Practices for the Provider Approach in Treating Patients With I…

Katherine Peters

Effective Strategies for Managing IDH-Mutant Gliomas

Matteo Simonelli

RANO 2.0 and Advances in Neuroimaging: Impact on Clinical Trials and…

Penn Medicine's 11th Neuro-Oncology Brain Tumor Symposium 2024

S. Mohan

IDH-Mutant Diffuse Glioma: Best Practices for Multidisciplinary Appr…

Ruham Nasany

Diagnosing IDH-Mutant Diffuse Glioma: Recent Classification Updates …

Ashley Aaroe

Surgical Approaches for Brain Tumors

Dana-Farber Cancer Institute

W. Linda Bi, O. Arnaout

BRAF/MEK Targeted Therapy in Adult and Pediatric Glioma: Insights an…

Johns Hopkins

K. Schreck

Key Practice-Changing Studies in Neuro-Oncology: Rapid Insights Acro…

Yale Cancer Center

N. Blondin

ASCO® 2024 Insights: "FIREFLY-1 Trial - Type II RAF Inhibitor Tovora…

2024 ASCO® Annual Meeting Insights Hub

D. Ziegler

Vorasidenib for Low Grade Gliomas

Stanford Medicine

T. Cao

Medical and Symptom Management of Patients With Brain Tumors

Penn Medicine's 11th Neuro-Oncology Brain Tumor Symposium 2024

A. Pruitt

Overcoming Barriers to Extend Survival: Promising Results of Clinica…

Penn Medicine's 11th Neuro-Oncology Brain Tumor Symposium 2024

S. Brem